Gilead Says 75.4% Of Livdelzi Recipients Achieve ALP Normalization At Week 52 Versus 16.1% Placebo

Nov 5 (Reuters) - Gilead Sciences, Inc. GILD.O:

• POSITIVE PHASE 3 IDEAL STUDY RESULTS FURTHER SUPPORT LIVDELZI®’S (SELADELPAR) IMPACT ON ACHIEVING ALP NORMALIZATION GOALS IN SECOND-LINE TREATMENT ACROSS A BROAD POPULATION OF PEOPLE LIVING WITH PRIMARY BILIARY CHOLANGITIS (PBC)

• GILEAD - 75.4% OF LIVDELZI RECIPIENTS ACHIEVE ALP NORMALIZATION AT WEEK 52 VERSUS 16.1% PLACEBO

• GILEAD - SERIOUS ADVERSE EVENTS 3.1% LIVDELZI VERSUS 12.9% PLACEBO; NONE RELATED TO DRUG

Further company coverage: GILD.O